PeproMene Bio

PeproMene Bio, Inc. is a clinical-stage biotech company focused on developing novel therapies for B-cell malignancies and autoimmune disorders. Their lead candidate, PMB-CT01 (BAFFR-CAR T cells), is in Phase 1 clinical trials for relapsed and refractory B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The company also develops BAFFR Bispecific T Cell Engager and BAFFR-CAR NK cells.

Buy Funded Startups lists

Funding Round:

Funding Amount: $11M

Date: 19-Dec-2024

Investors: Institute for Follicular Lymphoma Innovation

Markets: Biotechnology, Oncology, Cell Therapy, Health Care

HQ: Irvine, California, United States

Founded: 2016

Website: https://pepromenebio.com/

LinkedIn: https://www.linkedin.com/company/pepromene-bio

Twitter:

Instagram: